# Table of Contents

## Section 1. Introduction

| 1.1 | Sources of Procedural Information | 1-1 |
| 1.2 | Procedural Information | 1-1 |
| 1.3 | Investigator of Record (IoR) Responsibilities | 1-2 |
| 1.4 | Study Activation Process | 1-2 |

## Section 2. Documentation Requirements

| 2.1 | Essential Documents | 2-1 |
| 2.2 | Participant Research Records | 2-2 |
| 2.2.1 | Concept of Source Data and Source Documentation | 2-2 |
| 2.2.2 | Required Source Documentation | 2-2 |
| 2.2.2.1 | Chart Notes | 2-3 |
| 2.2.2.2 | Visit Checklists | 2-4 |
| 2.2.2.3 | Laboratory | 2-4 |
| 2.2.2.4 | Case Report Forms (CRFs) | 2-4 |
| 2.2.3 | Protocol Deviations | 2-4 |
| 2.2.4 | Document Organization and Participant Confidentiality | 2-5 |
| 2.3 | Study Product Accountability, Chain of Custody, and Dispensing Documentation in the Pharmacy | 2-6 |
| 2.3.1 | Record Retention Requirements | 2-7 |
| 2.4 | Appendices | 2-8 |
| Section Appendix 2-1: Source Documentation of Study Procedures | 2-8 |
| Section Appendix 2-2: CRFs Used as Source Documents | 2-11 |
| Section Appendix 2-3: CRFs Not Used as Source Documents | 2-12 |

## Section 3. Participant Accrual and Retention

| 3.1 | Pre-Screening Procedures | 3-1 |
| 3.2 | Participant Accrual | 3-2 |
| 3.2.1 | Study Accrual Plan and Site-Specific Accrual Targets | 3-2 |
| 3.2.2 | In-Depth Phone Interview Accrual Targets | 3-2 |
| 3.2.3 | Rectal Biopsy/Fluid Subset Accrual Targets | 3-2 |
| 3.2.4 | Accrual Tips and Reminders | 3-3 |
| 3.2.5 | Participant Accrual SOP | 3-3 |
| 3.3 | Participant Retention | 3-4 |
| 3.3.1 | Retention Definitions | 3-4 |
| 3.3.2 | Retention Requirements | 3-4 |
| 3.3.3 | Retention SOPs | 3-4 |
| 3.3.4 | Obtaining and Updating Locator Information | 3-5 |
| 3.3.5 | Retention Tips | 3-5 |
| 3.3.6 | Participants Who Voluntarily Discontinue Study Participation | 3-6 |

## Section 4. Informed Consent

| 4.1 | Overview of Informed Consent Requirements and Procedures | 4-1 |
| 4.2 | Site-Specific Informed Consent Forms | 4-2 |
| 4.3 | SOP for Obtaining Informed Consent | 4-2 |
Section 5. Study Procedures

5.1 Visit Considerations ................................................................. 5-1
5.2 Eligibility Determination .......................................................... 5-1
5.3 Visit Checklists ........................................................................ 5-3
  5.3.1 Sequence of Procedures ...................................................... 5-3
5.4 Screening Visit ......................................................................... 5-4
  5.4.1 Screening and Enrollment Timeframe ................................. 5-4
  5.4.2 Assignment of Participant ID Numbers ............................. 5-4
  5.4.3 Screening and Enrollment Log ........................................... 5-5
  5.4.4 Screening Visit Procedures ................................................ 5-5
  5.4.5 Participants Found to be Ineligible (Screen Failures) ........... 5-6
5.5 Enrollment Visit ...................................................................... 5-6
  5.5.1 Enrollment Visit Procedures .............................................. 5-6
    5.5.1.1 Random Assignment ................................................... 5-7
    5.5.1.2 Prescription Overview .................................................. 5-8
    5.5.1.3 Product Dispensation, Product Use Instructions, First Product Use, and Adherence Counseling ....... 5-9
5.6 Follow-up Visits ..................................................................... 5-9
  5.6.1 Types of Follow-up Visits .................................................... 5-9
  5.6.2 Follow-up Visit Scheduling ................................................ 5-9
    5.6.2.1 Target Visit Dates ........................................................ 5-9
    5.6.2.2 Visit Windows .............................................................. 5-10
    5.6.2.3 Visits Conducted Over Multiple Days: “Split Visits” ....... 5-10
    5.6.2.4 Missed Visits ............................................................... 5-11
  5.6.3 Follow-up Visit Procedures ................................................. 5-11
    5.6.3.1 Interim Visits ............................................................... 5-12
    5.6.4 Modified Visit Procedures for Participants Who Discontinue Product Use ............................... 5-12
      5.6.4.1 Participants Who Discontinue Product Use Either Voluntarily or per Investigator Discretion .... 5-12
      5.6.4.2 Participants Who Become Infected with HIV .............. 5-13
  5.6.5 Voluntary Withdrawal of Study Participation ...................... 5-14
    5.6.5.1 Resumption of Study Participation After Voluntary Withdrawal .................................................. 5-14

Section 6. Counseling and Behavioral Considerations

6.1 HIV Pre-/Post-Test Counseling ............................................... 6-2
6.2 Risk Reduction Counseling ...................................................... 6-3
6.3 Product Use Instructions and Protocol Adherence Counseling ................................................................. 6-4
  6.3.1 First Dose at the Initiate Period Visit for Each Product Use Regimen .................................................. 6-5
Section 7. Study Product Considerations for Non-Pharmacy Staff

7.1 Study Product Regimens .................................................................................................................. 7-1

7.2 Study Product Use Instructions ......................................................................................................... 7-2

7.2.1 Truvada Tablets ............................................................................................................................. 7-2

7.2.2 Daily Tenofovir Reduced Glycerin 1% Gel .................................................................................. 7-2

7.2.3 RAL-Associated Tenofovir Reduced Glycerin 1% Gel ................................................................. 7-3

7.2.4 Study Product Concerns .............................................................................................................. 7-3

7.3 Prescriptions and Dispensing Study Products at Initiate Period Visits ......................................... 7-3

7.4 Study Product Request Slip .............................................................................................................. 7-4

7.4.1 Study Product Re-Supply - Dispensing Study Products at Mid-Period Visits ......................... 7-4

7.4.2 Product Hold/Resume .................................................................................................................. 7-4

7.4.3 Permanent Discontinuation of Study Product .............................................................................. 7-5

7.4.4 Participant-Initiated Decline of Study Product ........................................................................... 7-5

7.4.5 Participant No Longer in Study .................................................................................................. 7-5

Appendices .................................................................................................................................................. 6-21

Section Appendix 1: Mock Participant ID’s ...................................................................................... 6-21

Section Appendix 2: SMS Test Passwords ......................................................................................... 6-22
Section 8. Clinical Considerations

8.1 Participant-Reported Medical History (Baseline [Pre-Existing Conditions] and during Follow up) .................. 8-2
  8.1.1 Pre-existing Conditions Review at Screening ................................................................. 8-2
  8.1.2 Pre-existing Conditions Review at Enrollment (time of randomization) ...................... 8-2
  8.1.3 Medical History Review during Follow Up ................................................................. 8-3
8.2 Participant-reported Medication History (Baseline and during Follow Up) .............................. 8-4
  8.2.1 Baseline Medication History .................................................................................. 8-4
  8.2.2 Medication History Review during Follow-Up ....................................................... 8-5
  8.2.3 Prohibited Medications and Products .................................................................. 8-5
8.3 Physical Exam .............................................................................................................. 8-6
8.4 Rectal Exam .................................................................................................................. 8-6
  8.4.1 Documentation of Rectal Exam Findings ................................................................. 8-6
  8.4.2 General Technique (Preparation and Position) ...................................................... 8-7
  8.4.3 Visual Examination of the Perianal Area ............................................................... 8-8
  8.4.4 Swab Collection for HSV Detection and HPV Typing ........................................ 8-8
  8.4.5 Digital Rectal Examination (DRE) ...................................................................... 8-8
8.5 Specimen Collection (applicable to all study participants) ........................................... 8-9
  8.5.1 Preparation of the Anoscope ............................................................................... 8-9
  8.5.2 Chlamydia trachomatis (CT)/ Neisseria gonorrhea (GC) ....................................... 8-9
  8.5.3 Rectal Sponge Collection for Adherence PK and PD ............................................ 8-10
8.6 Specimen Collection (applicable to Rectal Fluid/Tissue Subset only) .................................. 8-11
  8.6.1 Coagulation Testing (INR or PT) ........................................................................... 8-11
  8.6.2 Rectal Sponge Collection for Mucosal Immunology .............................................. 8-11
  8.6.3 Enema ............................................................................................................... 8-12
  8.6.4 Rectal Tissue (biopsies) Collection ........................................................................ 8-12
8.7 STI/RTI/UTI Management ............................................................................................. 8-14
8.8 Syphilis .......................................................................................................................... 8-14
8.9 HIV Testing at Screening ........................................................................................... 8-15
  8.9.1 Assessment of Acute HIV Infection ...................................................................... 8-15
  8.9.2 HIV Testing during Follow Up ............................................................................ 8-15
8.10 Hepatitis B Testing ......................................................................................................... 8-16
8.11 Hepatitis C antibody testing at Screening ........................................................................ 8-19
8.12 Management of Laboratory Test Results ................................................................. 8-19
  8.12.1 Calculating Creatinine Clearance Rates (Screening Only) ................................... 8-19
8.13 Clinical and Product Use Management ........................................................................ 8-19
Section 9. Adverse Event Reporting and Safety Monitoring

9.1 Definitions ..............................................................................................................9-1
  9.1.1 Adverse Event (AE) ...........................................................................................9-1
  9.1.2 Reporting AEs ..................................................................................................9-2

9.2 Serious Adverse Events (SAEs) / Expedited Adverse Events (EAEs) ....................9-2
  9.2.1 Reporting SAEs/EAEs .......................................................................................9-3
  9.2.2 Updating EAE Reports ......................................................................................9-5

9.3 Adverse Event Terminology ..................................................................................9-5

9.4 Reporting Laboratory Abnormalities as AEs ..........................................................9-6

9.5 AEs Involving Hospitalizations/Surgical Procedures ..............................................9-7

9.6 Adverse Event Severity Grading ..........................................................................9-7

9.7 Adverse Event Relationship to Study Product ......................................................9-8

9.8 Adverse Event Outcomes and Follow-Up Information: During the Study ..........9-8

9.9 Adverse Event Outcomes and Follow-Up Information: After Study Termination 9-9

9.10 Reporting Recurrent Adverse Events ..................................................................9-9

9.11 Social Harms .........................................................................................................9-9
  9.11.1 Addressing Reports of Social Harm .................................................................9-10

9.12 MTN-017 Safety Monitoring, Review, and Oversight ...........................................9-11

9.13 Safety Distributions from DAIDS .......................................................................9-11

9.14 Appendices ..........................................................................................................9-12
  Section Appendix 9-1: Resources for Safety and AE Reporting to DAIDS for the clinical research sites9-12
  Section Appendix 9-2: Roles and Responsibilities of the PSRT .............................9-13

Section 10. Laboratory Considerations

10.1 Overview and General Guidance .........................................................................10-2

10.2 Specimen Labeling ..............................................................................................10-6

10.3 Procedures for Specimens that cannot be Evaluated .........................................10-6

10.4 Use of LDMS .......................................................................................................10-6
  10.4.1 Off-Hours Contact Information .......................................................................10-6
  10.4.2 Logging in PK Samples ..................................................................................10-8

10.5 Urine Testing .......................................................................................................10-8
  10.5.1 Specimen Collection .......................................................................................10-8
  10.5.2 Urine Chlamydia and Gonorrhea Testing .......................................................10-9
    10.5.2.1 Instructions for transferring urine into the Gen-Probe UPT .......................10-9
    10.5.2.2 Instructions for transferring urine into the GeneXpert transport reagent tube10-9
  10.5.3 Dipstick Urinalysis .........................................................................................10-9

10.6 Blood Testing .....................................................................................................10-10
  10.6.1 Specimen Collection and Initial Processing ..................................................10-10
  10.6.2 HIV Testing ..................................................................................................10-10
  10.6.3 Hematology Testing ......................................................................................10-11
  10.6.4 Liver and Renal Function Testing ..................................................................10-11
  10.6.5 Syphilis Testing ............................................................................................10-11
  10.6.6 Hepatitis B Surface Antigen, Hepatitis B Surface Antibody, and Hepatitis C Antibody10-12
  10.6.7 HSV Serology ...............................................................................................10-12
  10.6.8 INR/PT (Tissue Subset only) ..........................................................................10-12
  10.6.9 Plasma Archive (baseline) and Plasma for Storage .......................................10-12
  10.6.10 Blood for Tenofovir PK ..............................................................................10-12
## 10.7 Testing of Rectal Specimens

- 10.7.1 Anal HSV-1/2
- 10.7.2 Anal HPV Typing (DNA PCR)
- 10.7.3 Rectal NAAT for Gonorrhea and Chlamydia
  - 10.7.3.1 Instructions for collection and transport of rectal swabs for GC/CT testing with Gen-Probe
  - 10.7.3.2 Instructions for collection and transport of rectal swabs for GC/CT testing with GeneXpert
- 10.7.4 Rectal Sponge for PK
- 10.7.5 Rectal Sponge for PD (and Mucosal Immunology* for tissue subset)
- 10.7.6 Rectal Biopsies for PD (Tissue subset only)
- 10.7.7 Rectal Biopsies for PK (Tissue subset only)
- 10.7.8 Rectal Biopsy for Histology (Tissue subset only)
- 10.7.9 Rectal Biopsy for Proteomics (Tissue subset only)
- 10.7.10 Biopsies for Mucosal T Cell Phenotyping (Tissue subset only)
- 10.7.11 Mucosal Gene Expression Array (Tissue subset only)

## 10.8 Appendices

Section Appendix 10-1: Procedure for preparing reagents for MTN-017

### Section 11. Data Collection

#### 11.1 DataFax Overview

#### 11.2 DataFax Form Completion

- 11.2.1 General Guidelines
- 11.2.2 How to Mark Response Boxes
- 11.2.3 How to Record Numbers
  - 11.2.3.1 How to Record Dates
  - 11.2.3.2 How to Record Time
- 11.2.4 Data Corrections and Additions
- 11.2.5 How to Handle Missing and Unknown Data
- 11.2.6 Faxing Data Fax Forms

#### 11.3 Non-DataFax Forms

#### 11.4 Form Storage

#### 11.5 MTN Data Management SOP

#### 11.6 Study-specific Data Collection

- 11.6.1 Participant ID Numbers (PTIDs)
- 11.6.2 Study Visit Timing
- 11.6.3 Visit Codes and Page Numbers
- 11.6.4 Staff Initials/Date
- 11.6.5 Form Supply
- 11.6.6 Case Report Form Completion Schedule
- 11.6.7 Completing Interviewer-administered Forms
- 11.6.8 Site Review (Quality Control) of DataFax Forms
  - 11.6.8.1 MTN-017 QC Review Step #1
  - 11.6.8.2 MTN-017 QC Review Step #2

#### 11.7 Form-specific Completion Instructions

#### 11.8 Case Report Forms

### Section 12. Data Communiqué

### Section 13. Study Reporting Plan

#### 13.1 Purpose of Reporting Plan

#### 13.2 Study Reports